As Tango moves toward clinic with $60M series B, another partnership could precede IPO

Although synthetic lethality company Tango’s $60 million series B round includes crossover investors who might normally signal that an IPO is in the offing, President and CEO Barbara Weber thinks the wealth of targets that the company’s platform has generated could point the way to another strategic partnership before the company attempts to go public.

Led by Boxer Capital of the Tavistock Group, Tango’s new round includes Cormorant Asset Management, Casdin Capital and Hillhouse Capital, as well as certain LPs of Tango’s founding investor Third Rock Capital. That firm did not invest directly in the series B; Weber is a venture partner at the firm...